CD5 and mature T-cell and NK-cell non-Hodgkin lymphoma: Encouragingly, a phase II trial of allogeneic CD5 CAR-T cells in r/r T-ALL (NCT05032599) demonstrated a 100% response rate in 16 patients, suggestive also of their potential utility in the treatment of CD5-positive PTCL [136].